Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

IASLC TTLC 2024

21–24 February 2024 | Santa Monica, CA

IASLC TTLC 2024

21–24 February 2024 | Santa Monica, CA
Novel immunotherapy combinations for SCLC 5:43
Novel immunotherapy combinations for SCLC
Ticiana Leal • 27 Feb 2024
Current standard of care for inoperable stage III NSCLC 0:35
Current standard of care for inoperable stage III NSCLC
Ticiana Leal • 27 Feb 2024
Why should consolidation radiotherapy be used in stage IV lung cancer? 2:41
Why should consolidation radiotherapy be used in stage IV lung cancer?
Puneeth Iyengar • 28 Feb 2024
Curative and palliative radiation in patients with NSCLC with cachexia 2:41
Curative and palliative radiation in patients with NSCLC with cachexia
Puneeth Iyengar • 28 Feb 2024
Advances in radiotherapy for lung cancer 1:16
Advances in radiotherapy for lung cancer
Puneeth Iyengar • 28 Feb 2024
Targeting NTRK and NRG in lung cancer treatment 2:39
Targeting NTRK and NRG in lung cancer treatment
Liza Villaruz • 28 Feb 2024
The future of TRK inhibitors in lung cancer treatment 1:16
The future of TRK inhibitors in lung cancer treatment
Liza Villaruz • 28 Feb 2024
Assessing NSCLC treatments in under-represented patient populations 1:53
Assessing NSCLC treatments in under-represented patient populations
Liza Villaruz • 28 Feb 2024
Combination therapies involving KRAS G12C inhibitors in lung cancer 1:18
Combination therapies involving KRAS G12C inhibitors in lung cancer
Alexander Spira • 15 Mar 2024
Novel non-KRAS G12C inhibitors in solid tumors 1:54
Novel non-KRAS G12C inhibitors in solid tumors
Alexander Spira • 15 Mar 2024
The role of DLL3-directed agents in treating SCLC 3:40
The role of DLL3-directed agents in treating SCLC
Ticiana Leal • 27 Feb 2024
Overview and advances in tumor treatment fields (TTFields) 1:44
Overview and advances in tumor treatment fields (TTFields)
Ticiana Leal • 27 Feb 2024
Delivery of tumor treatment fields (TTFields) in NSCLC 2:40
Delivery of tumor treatment fields (TTFields) in NSCLC
Ticiana Leal • 27 Feb 2024
An introduction to the MAPK signaling pathway and pan-RAF inhibitors 8:06
An introduction to the MAPK signaling pathway and pan-RAF inhibitors
Rajwanth Veluswamy • 20 Feb 2024
Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors 2:06
Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors
Rajwanth Veluswamy • 20 Feb 2024
Management options for patients with type II/III BRAF-mutated lung cancer 1:52
Management options for patients with type II/III BRAF-mutated lung cancer
Rajwanth Veluswamy • 20 Feb 2024
The content of VJOncology is intended for healthcare professionals